KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
07 Novembro 2023 - 8:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced it will participate in a fireside chat at the
following investor conferences:
- Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023
at 3:00 p.m. EST
- Jefferies London Healthcare Conference on Thursday, November
16, 2023 at 9:30 a.m. GMT
A live webcast of each presentation will be available on the
Company’s website at www.kalvista.com. An audio archive will be
available on KalVista’s website for 30 days following the
presentations.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista is developing sebetralstat as an
oral on-demand therapy for HAE attacks and has achieved target
enrollment for the phase 3 KONFIDENT clinical trial. In addition,
KalVista’s oral Factor XIIa inhibitor program represents a new
generation of therapies that may further improve the treatment for
people living with HAE and other diseases.
For more information about KalVista, please visit
www.kalvista.com.
For more information on the sebetralstat HAE on-demand Phase 3
KONFIDENT trial, please visit www.konfidentstudy.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including our Phase 3
KONFIDENT trial, and to obtain regulatory approvals for
sebetralstat and other candidates in development, the success of
any efforts to commercialize sebetralstat, the ability of
sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107844541/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024